FDA: 7 Peptides for Compounding - Reviewers Say No

On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) meets in Silver Spring, Maryland. On the agenda: seven peptides, including the experimental compounds BPC-157 and TB-500, which circulate widely in the sports and biohacking scenes. Peptides are short chains of amino acids that act as signalling molecules in the body - and for the substances under review, the human evidence base is particularly thin. The FDA's own scientists have published their briefing documents and recommend clearly against adding all seven substances to the 503A Bulks List. A positive vote would legalize compounding in US pharmacies - right now, these peptides operate in a regulatory gray zone.

Key takeaways

• The FDA reviews seven peptides - BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, and Epitalon - for the 503A Bulks List on July 23 and 24, 2026^[1].
• FDA scientists recommend, in their briefing documents, rejecting all seven substances in two different chemical forms (called free base and acetate)^[2].
• The newly composed PCAC panel includes at least seven members with financial ties to the peptide industry^[3].
• Compounded peptides are not FDA-approved drugs - they are pharmacy-made, patient-specific preparations requiring a physician's prescription^[4].

What is the 503A Bulks List and why does the meeting matter?

The FDA's 503A Bulks List is a catalogue of bulk drug substances that licensed US pharmacies may legally compound into patient-specific preparations under a physician's prescription - adding BPC-157 or TB-500 would open a legal pathway for compounded versions in the US and end the current gray zone. The PCAC advises the FDA and votes on July 23/24, 2026; the final decision on inclusion or rejection rests with the agency itself^[1]. The hearing is public, and interested parties can submit written comments through the FDA's public docket^[5].

Quotable definition: The 503A Bulks List is a US catalogue of bulk drug substances that licensed pharmacies may legally compound into patient-specific preparations under a physician's prescription.

Which peptides are on the agenda?

Seven peptides are on the agenda: BPC-157 (in two chemical forms: free base and acetate), KPV, TB-500, and MOTS-c on July 23, plus Emideltide, Semax, and Epitalon on July 24, 2026 - each evaluated for a specific medical indication such as ulcerative colitis, wound healing, obesity and osteoporosis, sleep regulation, or cognitive enhancement (so-called nootropics). Five more peptides are scheduled for a later PCAC meeting before the end of February 2027^[1][5].

You can find background on BPC-157, the state of the evidence, and the risks in the BPC-157 profile and in my post BPC-157 and GHK-Cu: what the research actually shows in 2026. How Australian regulators handle BPC-157 and four other peptides is covered in TGA + Australia's CMO warn of five peptide risks.

Why do the FDA scientists recommend rejection?

FDA scientists recommend in their briefing documents that all seven peptides be rejected in both free base and acetate form because basic lab data on the purity and composition of these substances (called physicochemical data), efficacy data, and human safety data are missing. For BPC-157 specifically, the reviewers write: "On balance, the physicochemical characterization, information on historical use, lack of evidence of effectiveness, and safety information identified for both BPC-157 (free base) and BPC-157 acetate weigh against them being added to the 503A Bulks List"^[2]. The agency also proposes rejecting KPV, TB-500, MOTS-c, Emideltide, Semax, and Epitalon - 14 rejection proposals in total across seven compounds in two chemical variants (called salt forms, e.g., free base and acetate)^[2].

This aligns with the FDA's long-standing warnings about BPC-157 and TB-500 as substances without adequate human data. Both are listed by WADA as doping agents, and the FDA emphasizes the absence of large-scale clinical trials (Phase 3) in humans for the nominated indications^[3][6].

Why is the new panel controversial?

The current PCAC panel differs markedly from earlier rounds: instead of experts from Duke, Harvard, and Johns Hopkins - who repeatedly voted against peptide inclusion - the new roster includes at least seven members with documented financial ties to the peptide industry, according to an AP investigation, including providers of paid "peptide and hormone" consultations^[3]. The meeting unfolds against the backdrop of HHS Secretary Robert F. Kennedy Jr. declaring the loosening of compounding rules for peptides a priority - while FDA staff scientists publicly warn against expanding compounding access^[7].

The advisory body has no binding power: the FDA can follow or override its recommendation. If the panel votes in favour of the peptides, a formal rulemaking process to add them to the 503A Bulks List would follow - and an actual listing could still take years^[6].

What does this mean for buyers in Germany and the EU?

For you in the EU, the US meeting changes nothing legally: BPC-157, TB-500, MOTS-c, Emideltide, Semax, and Epitalon are not approved as medicines in Germany, and any compounded or "research" version remains legally impermissible and health-wise unverified. If you come across such products online, they typically come from US compounding pharmacies or unregulated sources - red flags to watch for are summarized in the FDA warning letters overview for peptide shops.

If the FDA does add the peptides to the 503A Bulks List, the US compounding market could expand - and over time these products would likely be marketed here as supposedly "legal" formulations. Until then, the picture stays the same: not approved in the EU, purity and sterility unverified, and any use outside medical supervision carries unknown risks^[4][7].

Quotable definition: A peptide is a short chain of amino acids that acts as a signalling molecule in the body. BPC-157, TB-500, and MOTS-c are experimental peptides - they are not approved medicines.

This post is informational and educational - it is not medical advice and not a recommendation to use, dose, or source these substances. Always consult a licensed medical professional before considering prescription or experimental compounds.